Comparative Pharmacology
Head-to-head clinical analysis: LEVOPHED versus VAZCULEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOPHED versus VAZCULEP.
LEVOPHED vs VAZCULEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
Vazculep is a direct-acting vasoconstrictor that stimulates alpha-adrenergic receptors in vascular smooth muscle, causing peripheral vasoconstriction and increased blood pressure.
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
5 mg IV bolus followed by 2.5 mg/hour continuous IV infusion; titrate to mean arterial pressure ≥65 mmHg. Maximum infusion rate: 40 mg/hour.
None Documented
None Documented
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Terminal elimination half-life is 12 hours. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 24 hours. Dose adjustment is recommended for CrCl <30 mL/min.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Renal excretion of unchanged drug accounts for 70% and fecal/biliary excretion accounts for 30%. Approximately 15% of the dose is excreted as glucuronide conjugate in urine.
Category C
Category C
Vasopressor
Vasopressor